Kalaris Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell KLRS and other ETFs, options, and stocks.

About KLRS

Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. It is focusing on developing TH103, a novel anti-VEGF agent targeted at treating neovascular and exudative retinal diseases. 

CEO
Andrew Oxtoby
CEOAndrew Oxtoby
Employees
20
Employees20
Headquarters
Berkeley Heights, New Jersey
HeadquartersBerkeley Heights, New Jersey
Founded
Founded
Employees
20
Employees20

KLRS Key Statistics

Market cap
117.53M
Market cap117.53M
Price-Earnings ratio
-2.30
Price-Earnings ratio-2.30
Dividend yield
Dividend yield
Average volume
92.66K
Average volume92.66K
High today
$5.22
High today$5.22
Low today
$4.71
Low today$4.71
Open price
$5.08
Open price$5.08
Volume
88.96K
Volume88.96K
52 Week high
$11.88
52 Week high$11.88
52 Week low
$2.14
52 Week low$2.14

Stock Snapshot

The current Kalaris Therapeutics(KLRS) stock price is $5.22, with a market capitalization of 117.53M. The stock trades at a price-to-earnings (P/E) ratio of -2.30.

On 2026-05-24, Kalaris Therapeutics(KLRS) stock moved within a range of $4.71 to $5.22. With shares now at $5.22, the stock is trading +10.8% above its intraday low and 0.0% below the session's peak.

Trading volume for Kalaris Therapeutics(KLRS) stock has reached 88.96K, versus its average volume of 92.66K.

Over the past 52 weeks, Kalaris Therapeutics(KLRS) stock has traded between a high of $11.88 and a low of $2.14.

Over the past 52 weeks, Kalaris Therapeutics(KLRS) stock has traded between a high of $11.88 and a low of $2.14.

KLRS News

TipRanks 1d
Insider Move: Major Kalaris Therapeutics Stock Purchase Signals Growing Confidence

New insider activity at Kalaris Therapeutics ( (KLRS) ) has taken place on May 22, 2026. Start a conversation with TipRanks’ trusted, data-backed investment in...

Investing.com 1d
Kalaris Therapeutics director Akkaraju’s fund buys $1.18m stock - Investing.com

...

Kalaris Therapeutics director Akkaraju’s fund buys $1.18m stock - Investing.com

Analyst ratings

86%

of 7 ratings
Buy
85.7%
Hold
14.3%
Sell
0%

People also own

Based on the portfolios of people who own KLRS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.